SCYX logo

SCYNEXIS INC

SCYXNASDAQ
🏆 #4679 by market capEarnings Nov 3US Equity
$992.77▼ $30.97 (−3.12%)
Simulated price
🔔
Track SCYX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.1%
7d▲ 20539.7%
14d▲ 22084.8%
30d▲ 18149.4%
ytd▲ 19771.3%
1y▲ 11718.7%
🏦Market Cap
$29M
Small Cap
📈Revenue Growth (YoY)
+449.9%
High Growth
📊Gross Margin
100.0%
High
💵FCF Margin
-69.3%
Thin
⚖️P/S Ratio
1.5x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$979.26 – $1,004.43
52-Week Range
$3.53 – $9.12
Volume
$3.32B
Avg Volume
$2.64B
Shares Outstanding
6.3M
Next Earnings
Dec 1, 2026

Fundamentals Snapshot

Annual Revenue
$21M
Last Q Revenue
$235,000
P/E Ratio
-2.5
P/S Ratio
1.5x
EPS (TTM)
$-0.87
Dividend Yield
0.00%
Dilution (1yr)
+14.7%

Why Investors Own SCYX

  • ✓High-growth profile — revenue up +52.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 48% gross margin and 13% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SCYX logo

SCYNEXIS INC

SCYX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$21M▲ +449.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$16M▼ −56.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −78.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.4M▲ +14.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$19M▲ +$19M YoY
StockOtter · stockotter.space

About SCYNEXIS INC

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$959.92
▼ −3.3% Downside
High Target$1,119.02
Low Target$782.45
Based on 25 analysts

Latest News & Updates

🚀
Barron’s·2h ago

SCYNEXIS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift SCYX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

SCYNEXIS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.